Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Clinuvel Pharmaceuticals.
RELATED STOCKHEAD STORIES
Director Trades
Directors Trades: It’s a new financial year, so who’s hoping for better returns and who’s selling to pay a tax bill?
Health & Biotech
ScoPo’s Powerplays: Biogen drama, M&A action, and profit-taking coloured the week in healthcare
Health & Biotech
‘Miracle’ breakthrough in melanoma fight puts focus on ASX stocks in the skin cancer space
Director Trades
Directors’ Trades: Who bought their company’s ASX shares on market just 2 days post-IPO?
Health & Biotech
Clinuvel to study using Scenesse implant to help ‘moon children’
News
Afterpay just joined the top 20 ASX stocks; how many others were once small caps?
Experts
ScoPo’s health powerplays: ‘We said October was going to be volatile’
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
First patient with rare skin disorder receives Clinuvel drug
News
Top 50 ASX small caps of 2018: Where are they now?
Health & Biotech
Large caps deny they’re being outgunned by smaller peers in health R&D
Health & Biotech
Dr Boreham’s Crucible: Why Invex has all the right ingredients to possibly become a takeover target
Health & Biotech
Clinuvel ready to sell its skin disorder treatment in the US; next up — a treatment that might have cured Michael Jackson
News
The traps and the opportunities: How to play equity markets in a global pandemic
Health & Biotech
Health: Wheeler dealer Probiotec spending money to make money
Health & Biotech
